BRD3731

BRD3731

B654510-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

BRD3731 is a selective GSK3β inhibitor, with IC 50 s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders In Vitro BRD3731 is a GSK3β- selective inhibitor extracted from patent US20160375006A1, compound example 272. BRD3731 (1-10 μM; 24 hours) inhibits the phosphorylation of CRMP2 in SH-SY5Y cells. BRD3731 (20 μM; 24 hours) decreases β-catenin S33/37/T41 phosphorylation and induces β-catenin S675 phosphorylation in HL-60 cells. BRD3731 (10-20 μM; 7-10 days) impairs colony formation in TF-1 and increases colony forming ability in the MV4-11 cell lineMCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:GSK-3β 15 nM (IC 50 ) GSK-3α 215 nM (IC 50 )

BRD3731 是一种选择性 GSK3β 抑制剂，对 GSK3β 和 GSK3α 的 IC 50 s 分别为 15 nM 和 215 nM。BRD3731 可用于研究创伤后应激障碍（PTSD）、精神障碍、糖尿病和神经退行性疾病。

2056262-07-6(DMSO)

C24H31N3O

377.52 g/mol

CC1(CC2=C(C(=O)C1)C(C3=C(NN=C3N2)CC(C)(C)C)(C)C4=CC=CC=C4)C